Chronic kidney disease market estimated to grow at 19.6%, driven by pipeline agents aimed at unmet needs

With pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients, the chronic kidney disease (CKD) market is expected to grow at a 19.6% compound annual growth rate from $2.2bn in 2023 to $13.5bn in 2033 in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), according to the upcoming GlobalData report: Chronic Kidney Disease: Seven-Market Drug Forecast and Market Analysis.